

# Abschied und Ausblick 2021

**24.-26.02.2020**

**Steigenberger Airport Hotel Frankfurt**






# Team im HQ



## Study Design

(Total N = 1,600)



Randomization within 12 weeks of surgery; radiotherapy and/or endocrine therapy as per local standards.

\*Higher risk for recurrence defined as either:

- **Inoperable:** Inoperable breast cancer at presentation with residual invasive cancer in the breast.
- **Node-positive:** Metastatic disease in axillary node(s) following neoadjuvant therapy irrespective of presence or absence of residual invasive cancer in the breast.

### Stratification:

- Surgical status at presentation (operable vs inoperable)
- Post therapy pathologic nodal status (positive vs negative)
- Tumor hormone receptor status (positive vs negative)
- HER2-targeted therapy approach (single vs dual)

### Endpoints:

- **Primary:** Invasive disease-free survival (IDFS)
- **Secondary:**
  - Disease-free survival (DFS)
  - Distant recurrence-free interval (DRFI)
  - Brain metastases-free interval (BMFI)
  - Overall survival (OS)
  - Adverse events (AEs)
- **Exploratory:**
  - Patient reported outcomes (PROs)
  - Biomarkers associated with efficacy/safety
  - PK associated with efficacy/safety

# PiPPA: HR+/HER2+ neoadjuvant *PIK3CA* mutant

N= 65/-165

HR+  
HER2+

*PIK3Ca*  
mutant

R

Letrozole + trastuzumab+  
pertuzumab (FDC)  
+GDC0077

Letrozole +trastuzumab+  
pertuzumab (FDC)

surgery

Standard Chemotherapy  
+ anti-HER2

Samples


Samples

Samples

Day 14

18 weeks


# AKT inhibitor in lobular cancers



# Welche Auswertungen kommen?



Subgruppen-  
auswertungen  
GeparX  
PenelopeB  
GeparNUEVO  
Insema uvm.



Fasching et al. Annals Oncol 2020

# See you in Berlin und Wien, aber leider nur digital



BCC 2021

17<sup>TH</sup> ST. GALLEN INTERNATIONAL  
BREAST CANCER CONFERENCE 2021

Primary Therapy of Early Breast Cancer. Evidence, Controversies, Consensus

17 – 21 March 2021, online worldwide

We are going fully virtual

st.galleroncology conferences

ABCS6 ASCO BIG IBCSC SAKK

## ESMO BREAST CANCER VIRTUAL CONGRESS

ESMO  
BETTER SCIENCE  
BETTER MEDICINE  
BETTER PRACTICE

5-8 May 2021

**SAVE the DATE GBG**

**März 2022**

**SAVE the DATE AGO**

**März 2022**

## HERZLICHEN DANK AN UNSERE SPONSOREN

   **20.000**

    **10.000**

    **5.000**

A Sandoz Brand

HERZLICHEN  
**DANK!**

Allen Referenten  
Herrn Ruffer

Technik Team  
Encore

An das TEAM der GBG:

**Isabelle Seppi**  
Sandra Jentsch

Das Team im HQ zur Beantwortung Ihrer Fragen

Und alle, die an den Vorträgen mitgearbeitet  
haben: PM Team, Medizinisches Team, Medical  
Writing Team

Twitter: #GBG\_Forschung  
Website: [www.gbg.de](http://www.gbg.de)